Inventiva Raises Up To €348M To Fund Phase 3 NATiV3 Clinical Trial For MASH, Appoints New Chairman and Director
Portfolio Pulse from Benzinga Newsdesk
Inventiva has raised up to €348 million to fund its Phase 3 NATiV3 clinical trial for MASH, with €94.1 million already secured. The funds will advance the trial of lanifibranor in over 1,100 patients. Additionally, new board appointments have been announced.
October 14, 2024 | 7:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inventiva has secured significant funding to advance its Phase 3 NATiV3 clinical trial for MASH, with €94.1 million already raised. This funding will support the trial of lanifibranor in over 1,100 patients, with completion expected in 1H 2025. New board appointments may also influence company strategy.
The successful raising of €94.1 million, part of a larger €348 million financing, is crucial for advancing the Phase 3 trial of lanifibranor, a key product for Inventiva. The trial's progress and potential success could significantly impact Inventiva's market position. Additionally, the appointment of new board members may bring strategic changes, further influencing the company's direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100